Biotechnology

SERIAL INNOVATOR, EITAN KONSTANTINO JOINS GENESIS MEDTECH AS CTO OF VASCULAR INTERVENTIONS FRANCHISE

SINGAPORE, Jan. 7, 2022 /PRNewswire/ -- Genesis MedTech Group (Genesis or Group) has appointed Dr.Eitan Konstantino (Eitan) as CTO of Vascular Interventions to propel Genesis' technology innovation within the neurovascular, cardiovascular and peripheral vascular spaces. His role will include dev...

2022-01-07 23:00 3181

100% Recovery-GoldenBiotech Announces Topline Results from Unblinded COVID-19 Trial for Oral New Drug Antroquinonol in Hospitalized Mild, Moderate and Severe Patients

TAIPEI, Jan. 7, 2022 /PRNewswire/ -- Golden Biotechnology Corp.(TPEx:4132) ("GoldenBiotech", GBC), a leading Taiwanese biopharmaceutical company, announces that its Phase 2 COVID-19 trial for oral new drug Antroquinonol (HOCENA®) has achieved 100% recovery results of its primary outcome measure i...

2022-01-07 18:53 2243

InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development

BEIJING, Jan. 7, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company's latest development. Details are as follows: Morgan Stan...

2022-01-07 08:30 2102

LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases

SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based therapeutics, announced that it has executed a research collaboration agreement with Mayo Clinic for new drug development for rare liver diseases. LISCure has been conducting j...

2022-01-06 22:00 1620

Happiness Development Announces Financial Results for the Six Months Ended September 30, 2021

NANPING, China, Jan. 6, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) aChina-based company engaging in the business of production of nutraceutical and dietary supplements, providing e-commerce sales and e-commerce marketing solutions, and the s...

2022-01-06 21:00 3349

Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines

SHANGHAI, Jan. 6, 2022 /PRNewswire/ -- Nuance Pharma ("Nuance"or the "Company"), a specialty care focused biopharma with late late-stage clinical programs and existing commercial operations, today announced an agreement with Sino Health Pharmaceutical Limited ("Sino Health") , an affiliated compa...

2022-01-06 14:45 2737

Ascentage Pharma to Present at the J.P. Morgan 40th Annual Healthcare Conference

SUZHOU, China and ROCKVILLE, Md., Jan. 5, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its participation in and presentation at the 40th A...

2022-01-06 08:30 7161

Accro Bioscience inks over $50M series B round

SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Accro Bioscience (Suzhou) Co., LTD. ("Accro Bioscience"), aChina-based leading biotechnology company, announced that the company has recently raised over$50 million in an oversubscribed Series B round. The financing was led by Hongtai Aplus with partici...

2022-01-05 11:08 1532

BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics

SEOUL, South Korea, Jan. 4, 2022 /PRNewswire/ -- BIORCHESTRA and SK Biopharmaceuticals announcedtoday that they have forged a partnership to research and develop new therapeutic compounds targeting microRNAs [1] (miRNA) for a potential treatment of epilepsy.

2022-01-05 08:07 1896

Origin Agritech Announces Collaboration with BaoDao Feed Ltd. To Commercialize Nutrition Enhanced Corn

BEIJING, Jan. 4, 2022 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), an agriculture technology company, announced today that it has signed a collaborative agreement with BaoDao Feed Ltd. ("BaoDao"), a Chinese feed producer with500 million RMB in annual sales. U...

2022-01-04 22:10 1603

Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two phase I tri...

2022-01-04 17:28 1897

TCI's Golden Formula Has Won the Best Plant-Based Functional Product in the World Plant-Based Awards 2021

TAIPEI, Jan. 3, 2022 /PRNewswire/ -- In recent years, there has been a global trend of plant-based health care, which is known as vegetarian food in Taiwan. In the World Plant-Based Awards, jointly organized by FoodBev Media and Plant Based World Expo & Conference, TCI's Golden Formula won the be...

2022-01-04 09:00 2002

Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr.Anthony Yeh to the position of Chief Strategy Officer and Head ofChina business development (BD), where he will lead corpor...

2022-01-03 18:00 1871

GBB Closed the A Round Financing with Newly Joined FutureX Capital

HONG KONG, Dec. 31, 2021 /PRNewswire/ -- Great Bay Bio (GBB), an AI-enabled biotechnology company, announces the participation of FutureX Capital in its Series A round fundraising. Great Bay Bio finished A round financing of near USD 10 million o...

2021-12-31 20:44 3042

Landmark international innovation and entrepreneurship competition concludes in China's Chongqing with top prize worth 100 mln yuan

CHONGQING, China, Dec. 31, 2021 /PRNewswire/ -- Chongqing Liangjiang Collaborative Innovation Zone Mingyue Lake International Innovation and Entrepreneurship Competition concluded Thursday in Chongqing Liangjiang New Area. Contestants across the country leveraged their ideas and proposals to win ...

2021-12-31 19:15 2472

GenFleet Therapeutics Raises $75 Million in Series C Financing Led by Huagai Capital, to Advance Innovative Pipeline Highlighting Cutting-edge Therapies

SHANGHAI, Dec. 31, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company with a focus in cutting-edge therapies in oncology and immunology, today announced the completion of$75 million (~500 million RMB) series C financing. This round of financing is led by Huagai ...

2021-12-31 19:00 2054

China Medical System (867.HK)'s Latest MSCI ESG Rating Unchanged at AA, Leading the Industry Globally

HONG KONG, Dec. 30, 2021 /PRNewswire/ -- Recently, Morgan Stanley Capital International (MSCI), the world's largest index provider, has updated the Environmental, Social and Governance (ESG) rating of China Medical System Holdings Limited ("CMS" or the "Company").CMS's latest rating remains uncha...

2021-12-30 20:00 2340

Peijia Medical's New Milestone Asia's first successful clinical case using HighLife transseptal mitral valve replacement technology

SUZHOU, China, Dec. 30, 2021 /PRNewswire/ -- On December 22, 2021, the first clinical case using HighLife transseptal mitral valve replacement ("TSMVR") technology was successfully carried out inAsia. The implantation of Peijia's Highlife TSMVR system was performed by ProfessorMao Chen and his te...

2021-12-30 19:18 3148

EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH

* Establishment of Joint Venture Company named SanPlena in the US * Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. SirStephen Bloom , world-renowned researcher in the field of obesity and metabolism at Imp...

2021-12-28 22:00 1954

Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology

SHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company,announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, smal...

2021-12-28 09:00 1415
1 ... 90919293949596 ... 129